New York State is following the new CDC guidelines, allowing more people to get the coronavirus vaccine, but Gov. Andrew Cuomo warns the state will not be able to keep up with demand; CBS2's Carolyn Gusoff reports.
Additional Secretary of Health Ministry Manohar Agnani informed that a total of 580 adverse events were reported post-vaccination drive. He said, "A cumulative of 580 Adverse Events Following Immunisation (AEFIs) has been reported. Of which 7 have been hospitalised."
At least 1,65,714 healthcare beneficiaries received COVID-19 jab on Saturday across India, marking it as a historic and biggest COVID-19 vaccination drive launched by Prime Minister Narendra Modi. About 16,755 total vaccinators involved across India during the COVID vaccination drive. There was no post adverse event reported after the vaccination was administered to the people. "Total vaccinators involved across India were 16,755. Total beneficiaries vaccinated across India--1,65,714. COVID19 vaccination drive was successful on Day 1. No case of post-vaccination hospitalisation reported so far," said Manohar Agnani, Additional Secretary of Union Health Ministry. "The Serum Institute of India (SII) produced COVISHIELD was supplied to all States and Union Territories (UT). Bharat Biotech's COVAXIN was supplied to 12 States. Total 3,351 sessions were held across the country with both the vaccines, said Health Ministry on COVID19 vaccine roll-out," he added. Watch the full video for more details.
Credit: HT Digital Content Duration: 06:46Published
On Day 1 of India's Covid-19 vaccination, two doctors who took the shots shared their experience. Dr Atul Peters and Anil Dhar of Max hospital were given Bharat Biotech's Covaxin and SII-made Covishield jabs respectively. Both didn't experience any side-effects and said that doubts regarding the inoculants are unfounded. Dr Suranjit Chatterjee of Apollo hospital, who is set to receive a shot soon, also weighed in on the controversy regarding Covaxin and its third phase trials. Watch the full video for more.
Credit: HT Digital Content Duration: 08:15Published
After Nepal government approved emergency use of Covishield vaccine, people are hoping the pandemic will falter and human lives would be back on track. Nepal's Department of Drug Administration on Friday issued a release giving information on approving Covishield developed by AstraZeneca and Oxford University, which will be manufactured by Serum Institute of India (SII) in India. Drug regulating authority has also specified Serum Institute of India for importers provided with low cost in purchasing and delivery of vaccine to public. Approving the vaccine for conditional purpose, the department has also asked manufacturers or importers to get approval for registration in order to bring the vaccines. Nepal imposed nationwide and partial lockdown for most of 2020 with rise in imported cases which later took the form of local transmission spreading mostly in urban areas and major cities. The nationwide lockdown which started in March 2020 hampered daily life of people as well as businesses. They now expect to thrive with the approval of vaccine. Though the detailed inoculation plan of Nepal Government is yet to be disclosed, a total of 3 companies applied for approval to take steps forward with Serum Institute for import of vaccines. India has already made conditional emergency approval for Covishield manufactured by the Serum Institute. Being one of the largest producers of vaccines at low cost, India has promised to provide vaccine to its neighbours in near future.
Britain's vaccine rollout is limited by a "lumpy" manufacturing process with production changes by Pfizer and a delay by AstraZeneca that could lead to brief supply disruption, Vaccine Deployment Minister Nadhim Zahawi said on Monday. Ciara Lee reports
Monica Calazans, a 54-year-old nurse in Sao Paulo, became on Sunday the first person to be inoculated in Brazil, receiving the Chinese vaccine known as CoronaVac after Brazilian health regulator Anvisa approved emergency use of COVID-19 vaccines from China's Sinovac Biotech Ltd and Britain's AstraZeneca.
Vaccines minister Nadhim Zahawi has suggested that a gradual easing oflockdown restrictions will not begin before early March. He told BBCBreakfast: “If we take the mid-February target, two weeks after that you getyour protection, pretty much, for the Pfizer/BioNTech, three weeks for theOxford/AstraZeneca, you are protected. “One of the things we don’t know yet,and the deputy chief medical officer Jonathan Van-Tam is on record as saying‘look give me a couple of months and I’ll tell you’, is the impact of thevaccine on transmission rates ie on infecting people. “So there are a numberof caveats that stand in the way of us reopening the economy. “It will begradually, it will be probably through the tiered system but you’re looking atthat sort of period, two to three weeks after the middle of February, afterwe’ve protected the top four cohorts.”
Credit: PA - Press Association STUDIO Duration: 00:53Published
Urging the people to have faith in India's researchers, scientists, regulatory authorities, All India Institute of Medical Sciences (AIIMS) Director Dr Randeep Singh Guleria on Saturday reassured the nation that Bharat Biotech's COVAXIN vaccine is safe. Dr Guleria along with NITI Aayog member VK Paul were administered the COVID-19 vaccine shot at AIIMS Delhi on the inaugural day of the nationwide roll-out of vaccination on Saturday. Talking about the experience, he said, "I am humbled to get vaccinated in the first slot and feel so proud. I hope more and more people come forward when it comes to getting vaccinated so that we can reduce mortality and prevent the spread of COVID-19 infection." Dr VK Paul said that the vaccine is safe and people should trust the scientific process. Watch the full video for more details.
Credit: HT Digital Content Duration: 03:41Published
Covishield and Covaxin, the two Covid-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects... IndiaTimes Also reported by •Hindu •DNA